This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
home:othertreatments:boneagents [10.24.2009] – external edit 127.0.0.1 | home:othertreatments:boneagents [10.25.2010] – paulalbert | ||
---|---|---|---|
Line 3: | Line 3: | ||
- | <html>< | + | <relatedarticle> [[home: |
A variety of medications including the bisphosphonates have been touted to conserve or increase bone mass. These drugs have a number of side effects and are known or suspected to interfere with proper immune function. | A variety of medications including the bisphosphonates have been touted to conserve or increase bone mass. These drugs have a number of side effects and are known or suspected to interfere with proper immune function. | ||
- | |||
- | |||
===== Bisphosphonates ===== | ===== Bisphosphonates ===== | ||
Bone has constant turnover, and is kept in balance (homeostasis) by osteoblasts creating bone and osteoclasts digesting bone. Bisphosphonates inhibit the digesting of bone by osteoclasts. | Bone has constant turnover, and is kept in balance (homeostasis) by osteoblasts creating bone and osteoclasts digesting bone. Bisphosphonates inhibit the digesting of bone by osteoclasts. | ||
- | Bisphosphonates have a variety of side effects: | + | The bisphosphonate has a variety of side effects: |
* chronic musculoskeletal pain(({{pubmed> | * chronic musculoskeletal pain(({{pubmed> | ||
* atrial fibrillation – Numerous studies have shown that the frequency of atrial fibrillation increases with increasing age in both men and women. Data from the Framingham Heart Study showed a greater biennial incidence of AF with increasing age, with the odds ratio rising by a factor of 2.2 for every additional 10 years of age.(({{pubmed> | * atrial fibrillation – Numerous studies have shown that the frequency of atrial fibrillation increases with increasing age in both men and women. Data from the Framingham Heart Study showed a greater biennial incidence of AF with increasing age, with the odds ratio rising by a factor of 2.2 for every additional 10 years of age.(({{pubmed> | ||
* calcium deposition in the soft tissues(({{pubmed> | * calcium deposition in the soft tissues(({{pubmed> | ||
- | * reduced organ function, e.g. renal dysfunction or failure | ||
* osteonecrosis of the jaw, i.e. bone death | * osteonecrosis of the jaw, i.e. bone death | ||
+ | * reduced organ function, e.g. renal dysfunction or failure | ||
Those patients with elevated 1,25-D – which is [[home: | Those patients with elevated 1,25-D – which is [[home: | ||
All these meds have some effect on the immune or endocrine system and are, therefore, to be avoided. | All these meds have some effect on the immune or endocrine system and are, therefore, to be avoided. | ||
- | |||
==== Types of bisphopshonates ==== | ==== Types of bisphopshonates ==== | ||
Line 32: | Line 29: | ||
* risedronate (Actonel) | * risedronate (Actonel) | ||
* tiludronate (Skelid) | * tiludronate (Skelid) | ||
+ | * zoledronic acid (Zometa, Zomera, Aclasta and Reclast) | ||
Line 45: | Line 42: | ||
{{tag> | {{tag> | ||
- | |||
- | |||
- | |||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
EDIT | EDIT | ||
- | * Legacy content | + | FDA Alert - Oral Bisphosphonates: |
- | * | + | |
===== References ===== | ===== References ===== | ||
- |